Dublin, May 30, 2017 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Hemophilia Disease Forecast and Market Analysis to 2035" report to their offering. Hemophilia is a relatively rare hereditary genetic disorder characterized by an inability to produce a clot capable of stopping bleeding. Mainly men are affected by hemophilia A (factor VIII-deficient) and hemophilia B (factor IX-deficient), as is the case with most recessive, X-chromosomal disorders. In congenital hemophilia, the impaired production or functioning of one of the factors involved in the coagulation cascade is responsible for compromised blood coagulation, leading to uncontrolled and prolonged bleeding. The current standard of treatment for these patients is the replacement of the missing factor via clotting factor concentrate products. However, some patients develop antibodies against these therapies, called inhibitors, making treatment much more difficult. Patients without hemophilia who develop inhibitors against clotting factor VIII or factor IX are diagnosed as having acquired hemophilia A or B, respectively. Although acquired hemophilia patients and congenital hemophilia patients with inhibitors share some similar traits and treatment options, acquired hemophilia affects men and women similarly, and has a distinct bleeding pattern. Another disease associated with blood coagulation dysfunction is von Willebrand disease, which is caused by a deficiency in von Willebrand factor. Although von Willebrand disease is more common than hemophilia, it is relatively less severe, with most patients exhibiting mild disease that does not require regular treatment unless bleeding episodes caused by trauma or invasive procedures are uncontrollable. Key Topics Covered: 1. FORECAST: HEMOPHILIA Executive Summary Market Overview and Trends Methodology and Market Definition Advate Adynovate Alprolix BAX 817 BAY 94-9027 BeneFIX CSL627 Eloctate FEIBA Idelvion Ixinity Kogenate/Helixate and Kovaltry N8-GP N9-GP NovoEight NovoSeven Nuwiq Rixubis Vonvendi Xyntha/ReFacto Primary Research Methodology 2. TREATMENT: HEMOPHILIA Executive Summary Primary Research Methodology Disease Definition and Diagnosis Patient Segmentation Current Treatment Options Prescribing Trends 3. EPIDEMIOLOGY: HEMOPHILIA Executive Summary Disease Background Sources and Methodology Forecast: Hemophilia Forecast: Von Willebrand Disease Epidemiologist Insight Strengths and Limitations Appendix 4. MARKETED DRUGS: HEMOPHILIA Executive Summary Product Overview Products Approved for Acquired Hemophilia Products Approved for Von Willebrand Disease Appendix Product profile: Advate Product profile: Adynovate Product profile: Alprolix Product profile: BeneFIX Product profile: Eloctate Product profile: FEIBA Product profile: Idelvion Product profile: Ixinity Product profile: Kogenate FS Product profile: NovoEight Product profile: NovoSeven Product profile: Rixubis Product profile: Xyntha 5. PIPELINE: HEMOPHILIA Executive Summary Clinical Pipeline Overview Target Product Profile Clinical Trial Design Product profile (late stage): BAX 817 Product profile (late stage): BAY 94-9027 Product profile (late stage): CSL627 Product profile (late stage): CSL689 Product profile (late stage): Kovaltry Product profile (late stage): LR769 Product profile (late stage): N8-GP Product profile (late stage): N9-GP Product profile (late stage): emicizumab 6. APPENDIX Appendix: Pipeline: Hemophilia For more information about this report visit http://www.researchandmarkets.com/research/5lb7vb/hemophilia
CONTACT: Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Related Topics: Hematological Drugs
